entertainment -WSS

entertainment

author：entertainment 2025-09-03 15:23:55 - browse：4781

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

hotspot

WSS

STAT Readout: Friday, Oct. 20 biotech updates

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

He's 19 months old and has one of the world’s rarest diseases

Readout LOUD podcast: Live from the 2023 STAT Summit

STAT Summit: The economic case for universal basic health care

Immune cells and nerve overgrowth may explain recurring UTI pain

entertainment

entertainment

explore

Continuity nursing helped my family in our darkest PICU moments

A new approach to psychiatric drug development

Apple is now the first public company to be valued at $3 trillion

Roche acquires Telavant from Roivant, adding experimental IBD treatment

New air purifier tech could be key to improving indoor air quality

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT Summit: The economic case for universal basic health care

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The public health thinking behind the CDC’s new Covid guidance

focus

STAT Summit: Ending the crisis of Black deaths in the U.S.

$1 billion proposal to grow Boston, Massachusetts biotech

Readout Newsletter: BridgeBio, Akero, and human embryo models

Ancient Greek ideas underpin modern concepts of pregnancy

STAT Summit: The economic case for universal basic health care

Streamlined flu vaccines recommended by FDA advisory panel

hotspot

hotspot

focus

leisure time